 |
      |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
In patients with glaucoma, elevated IOP is the only risk factor that may be treated to prevent vision loss. The most common treatment to lower elevated IOP is medication in the form of eyedrops like ALPHAGAN® P 0.1%. These medications decrease IOP, either by reducing the production of aqueous humor within the eye or by increasing the drainage of it from the eye. Laser treatment or even surgery may be needed when medical treatment alone is insufficient. |
|
|
Indication: ALPHAGAN® P 0.1% ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Important Safety Information Contraindication: ALPHAGAN® P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Precautions: Although ALPHAGAN® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. Adverse reactions: Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse events occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. Please click here for full product information. |
|
|
©2009 Allergan, Inc., Irvine, CA 92612 | ® marks owned by Allergan, Inc. |